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Abstract
Background
TolT was originally described as a Trypanosoma cruzi molecule that accumulated on the try-
pomastigote flagellum bearing similarity to bacterial TolA colicins receptors. Preliminary bio-
chemical studies indicated that TolT resolved in SDS-PAGE as ~3–5 different bands with
sizes between 34 and 45 kDa, and that this heterogeneity could be ascribed to differences
in polypeptide glycosylation. However, the recurrent identification of TolT-deduced peptides,
and variations thereof, in trypomastigote proteomic surveys suggested an intrinsic TolT
complexity, and prompted us to undertake a thorough reassessment of this antigen.
Methods/Principle findings
Genome mining exercises showed that TolT constitutes a larger-than-expected family of
genes, with at least 12 polymorphic members in the T. cruzi CL Brener reference strain and
homologs in different trypanosomes. According to structural features, TolT deduced pro-
teins could be split into three robust groups, termed TolT-A, TolT-B, and TolT-C, all of them
showing marginal sequence similarity to bacterial TolA proteins and canonical signatures of
surface localization/membrane association, most of which were herein experimentally vali-
dated. Further biochemical and microscopy-based characterizations indicated that this
grouping may have a functional correlate, as TolT-A, TolT-B and TolT-C molecules showed
differences in their expression profile, sub-cellular distribution, post-translational modifica-
tion(s) and antigenic structure. We finally used a recently developed fluorescence magnetic
beads immunoassay to validate a recombinant protein spanning the central and mature
region of a TolT-B deduced molecule for Chagas disease serodiagnosis.
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Conclusion/Significance
This study unveiled an unexpected genetic and biochemical complexity within the TolT fam-
ily, which could be exploited for the development of novel T. cruzi biomarkers with diagnos-
tic/therapeutic applications.
Author summary
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a lifelong and debilitating
neglected illness of major significance in Latin America, for which no vaccine or adequate
drugs are yet available. Identification of novel biomarkers able to transcend the current
limits of diagnostic and/or therapeutic assessment methods hence surfaces as a main pri-
ority in Chagas disease applied research. In this framework, we herein undertook a thor-
ough biochemical and antigenic characterization of T. cruzi TolT surface antigens. Our
results unveil an unexpected complexity within this family, with at least 12 polymorphic
TolT genes in the T. cruzi CL Brener reference strain genome. According to structural fea-
tures, TolT deduced molecules could be split into three robust groups that show differ-
ences in their structural features, expression profile, sub-cellular distribution, post-
translational modification(s) and antigenic structure. Overall, we show that TolT mole-
cules are conspicuously expressed by both major mammal-dwelling stages of the parasite,
and that they are differentially recognized by the immune system in Chagasic patients and
in T. cruzi-infected mammals. Our findings are discussed in terms of the evolution and
possible structural/functional roles of TolT molecules, as well as in terms of their applica-
bility in Chagas disease serodiagnosis.
Introduction
With ~6 million people already infected and ~100 million at risk of infection, Chagas disease
constitutes the most important parasitic disease and leading cause of infectious cardiomyopa-
thy in Latin America [1]. Migratory trends of infected populations from endemic areas to
Europe, North America, and the Western Pacific have also led to the spreading of this illness,
which is now recognized as an emerging threat to global public health [2]. Trypanosoma cruzi,
the etiological agent of Chagas disease, is a protozoan parasite that transitions between verte-
brates (including humans) and blood-sucking triatomine vectors, with different developmen-
tal stages involved in each host. Within the insect, two major developmental forms can be
observed: replicative epimastigotes in the midgut and metacyclic trypomastigotes in the hind-
gut [3]. The latter forms bring the infection into mammals when deposited on the skin or
mucosa along with the excreta of the bug during blood-feed. Following cell invasion, parasites
differentiate into rounded amastigote forms [3]. Along this transformation, the parasite under-
goes remarkable physiological and morphological changes [4], including the complete disposal
of its flagellum [5]. After several rounds of replication and just before disruption of the para-
site-laden cell, amastigotes differentiate back into non-dividing and highly motile bloodstream
trypomastigotes, which disseminate the infection within the mammal and may be eventually
taken up by the triatomine during a bloodmeal.
Following a 30–60 day-long acute phase, strong and parasite-specific immunity is elicited
in T. cruzi-infected people [6]. However, the parasite ability to quickly invade a wide variety of
TolT antigens in Trypanosoma cruzi
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cell types, and the concurrent deployment of multiple elaborated evasion systems turn this
immune response only partially effective [6,7]. In this context, the surface coat of bloodstream
trypomastigotes fulfills a key dual purpose: to interact with host cell receptors prior to parasite
internalization, and to provide protection against mammalian host-derived defense mecha-
nisms [7]. This coat is composed of densely packed glycosylphosphatidyl inositol (GPI)-
anchored glycoconjugates, which are usually coded by large, polymorphic, and developmen-
tally regulated gene families [8]. In quantitative terms, the most important trypomastigote coat
glycoproteins are mucins, Gp85/trans-sialidases (TS) and mucin-associated surface proteins
(MASPs), all of which distribute over the entire parasite cell body, the flagellum, and even the
flagellar pocket [8].
In 1990, a novel type of T. cruzi trypomastigote antigen was identified [9]. This antigen
turned out to display homology to bacterial TolA proteins [10], and was accordingly desig-
nated TolT (TolA-like protein from T. cruzi). Instead of showing a broad surface distribution,
TolT localized exclusively to the trypomastigote flagellum [9], apparently in the part of this
structure in contact with the parasite body. Western blot analysis showed that TolT actually
consisted of ~3–5 different molecules with sizes between 34 and 45 kDa [9]. All of them how-
ever collapsed to a single species upon treatment with endoglycosidase H, suggesting they
corresponded to identical and/or highly similar polypeptides undergoing differential glycosyl-
ation. Subsequent immunological screenings led to the identification of three genes (termed
TolT 1–3) in the T. cruzi Esmeraldo strain, which were arranged in tandem following a head-
to-tail disposition [11]. Two of these genes, TolT1 and TolT2 were identical at the nucleotide
level, and showed 98.9% sequence identity with respect to TolT3 [11]. The recurrent identifica-
tion of peptides showing slight variations to TolT 1–3 deduced sequences in recent proteomic
surveys however hinted at an underestimated TolT complexity [12–16].
The complete DNA sequence of the T. cruzi CL Brener reference clone was released in
2005, and it is represented by two datasets of contigs, each corresponding to one parental hap-
lotype, which are referred to as ‘Esmeraldo-like’ or ‘non-Esmeraldo-like’ [17]. The CL Brener
genome revealed a highly repetitive structure, which corresponded to a marked expansion of
transposable elements, satellite DNA, and large multigene families including the above men-
tioned mucins, TS and MASPs, usually organized in tandems [17]. These features, together
with CL Brener hybrid nature resulted in a highly fragmented genome assembly [17]. The CL
Brener genome was subsequently followed by that of distinct parasite strains/clones [18,19],
and by the genomes of phylogenetically related organisms [20–23]. More recently, third-gener-
ation sequencing technologies and bioinformatics allowed high-quality genome assembly of
T. cruzi genomes [24–26]. This wealth of genetic information, along with the pressing need of
novel T. cruzi biomarkers [27], prompted us to revisit TolT.
In this work, we show that TolT constitutes a larger-than-expected family of genes in T.
cruzi, with at least 12 polymorphic members in the CL Brener reference strain and homologs
in different trypanosomes. According to structural features, TolT deduced proteins could
be split into three robust groups, all of them showing homology to bacterial TolA proteins,
a biased amino acid composition, canonical signatures of surface localization and/or secre-
tion, and trypomastigote flagellar surface localization. All of them were also found to be
expressed in amastigote forms, with a TolT group-specific sub-cellular distribution.
Thorough biochemical and immunological characterizations indicated that distinct TolT
groups show additional differences in their post-translational modification(s) and antigenic
structure. We finally used a recently developed fluorescence magnetic beads immunoassay
to validate a recombinant TolT-B protein as an appealing reagent for Chagas disease
serodiagnosis.
TolT antigens in Trypanosoma cruzi
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Materials and methods
In silico predictions and phylogeny analyses
DNA sequences were compared using BLAST tool at the NCBI non-redundant DNA
sequences databases at TriTrypDB (http://tritrypdb.org/tritrypdb/) and GeneDB (http://www.
genedb.org/) using TolT1 (GeneBank accession number AF099099) sequence as query.
Sequences showing an E value< 10−5 (~40% identity) were retrieved and their complete
open reading frames (ORFs) were aligned using T-Coffee. After manual curation of the output,
a preliminary phylogenetic tree was built using the Neighbor-Joining method. This tree
allowed the definition of 3 robust groups, termed TolT-A, TolT-B and TolT-C. The complete
ORF of one representative member of each group (TolT-A: TcCLB.508767.20, TolT-B:
TcCLB.510433.20, TolT-C: TcCLB.506815.20) was further used to perform ‘iterative’ screen-
ings, using the same conditions as stated above. The final phylogram (made upon DNA
sequences) is the consensus tree of 1,000 bootstrap replicates and was graphically modified for
presentation using iTOL. In addition, the deduced polypeptide of each representative member
was used to search for similar sequences in the protein databases at TriTrypDB and GeneDB.
Identification of signal peptides (SP) and GPI-anchoring signals was done using the online
servers SignalP 4.0 and PredGPI, respectively. Post-translational modifications were predicted
using NetPhos 3.1, NetNGlyc 1.0, NetOGlyc 4.0 and CSS-Palm 3.0. Homology to TolA was
evaluated by independently querying the bacterial database of UniProt (http://www.uniprot.
org/blast/) under default conditions with each predicted TolT product. Logos were generated
using WebLogo (http://weblogo.berkeley.edu/logo.cgi).
Parasite stocks and cell lines
CL Brener developmental forms were obtained and purified as described [28]. Briefly, epimas-
tigotes were grown at 28˚C in brain-heart tryptose medium supplemented with 10% (v/v)
heat-inactivated fetal calf serum (FCS). Cell-derived trypomastigotes (henceforth trypomasti-
gotes) and extracellular amastigotes were harvested from the supernatant of Vero cells
(ATCC) grown at 37˚C and 5% CO2 in minimal essential medium (MEM) supplemented with
10% (v/v) FCS, 0.292 g/L L-glutamine, 100 IU/mL Penicillin and 100 μg/mL Streptomycin (all
from GIBCO Laboratories).
DNA extraction and gene amplifications
T. cruzi genomic DNA from CL Brener epimastigotes was purified as described [29]. Gene
amplifications were obtained by PCR using 1–10 ng of DNA as template, recombinant Taq
DNA Polymerase (Invitrogen), and the oligonucleotides detailed in S1 Table.
RNA extraction, cDNA preparation and Real-time quantitative PCR (RT-
qPCR)
Different parasite developmental forms (4 x 108 of each) were homogenized in 1 mL of TRIzol
reagent (Thermo), treated with DNAse I (Sigma), further partitioned in chloroform and cen-
trifuged at 12,000 x g. The aqueous phase was recovered and RNA integrity was evaluated by
1% agarose gel electrophoresis. RNA was precipitated with 1 mL of 2-propanol. First strand
cDNA was synthesized from total RNA samples using Superscript II reverse transcriptase
(Life Technologies). Briefly, total RNA was resuspended in RNAse-free H2O and used at a
final concentration of 0.25 μg/μL (3 μg of RNA per reaction), 10 μM oligo-dT-anchor primer
(S1 Table), and 10 mM dNTPs in the reverse transcriptase (RT) First Strand Synthesis kit
(Sigma). RT reactions were diluted appropriately, and used as templates for Real-Time
TolT antigens in Trypanosoma cruzi
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quantitative PCR (RT-qPCR) reactions using Kapa Sybr Fast Universal Kit (Biosystems) and
primers (S1 Table) were designed using PerlPrimer software v1.1.21. To verify that the SYBR
Green dye detected only one PCR product, all the reactions were subjected to the heat dissocia-
tion protocol after the final cycle of the PCR and sequenced [30]. Samples were tested against
T. cruzi Calmodulin and Glyceraldehyde 3-phosphate dehydrogenase (TcGAPDH) as refer-
ence genes for data normalization (S1 Table). Each experiment was performed in triplicate for
two independently generated sets of cDNA templates.
Cloning procedures
PCR amplicons corresponding to TolT molecules were cloned into the pGEM-T easy vector
(Promega), and used to transform DH5α cells (Invitrogen). DNA sequencing was carried out
at Macrogen. These amplicons were then digested with the indicated restriction enzymes (S1
Table) and cloned into a tailored version of pGEX-2T (GE Healthcare) [31]. The glutathione
S-transferase (GST)-fusion protein bearing the repetitive domain of T. cruzi antigen 1 (Ag1,
also known as FRA, JL7 or H49 [27]) has been described [32].
Expression of recombinant proteins in bacteria and antibody development
Soluble fractions of E. coli strain BL21-Codon Plus (DE3)-RP cultures induced for 3 h at 28˚C
with 0.1 mM isopropyl ß-D-thiogalactopyranoside (Fermentas) were purified by gluthatione-
Sepharose chromatography (GE Healthcare) and dialyzed against PBS [32,33]. GST, GST-Ag1,
and GST-TolT samples were quantified by Bradford reagent (Bio-Rad) and purity was assessed
by Coomasie blue-stained SDS-PAGE. Purified GST-TolT proteins were injected into animals
as described [34] to generate specific antisera (S2 Table). Antiserum to T. cruzi TSSA has been
described [35].
Indirect immunofluorescence (IIF) assays
For IIF assays, trypomastigote forms (~106) were harvested, washed in PBS, adhered to poly-
L-lysine (Sigma)-coated cover-slips and fixed for 30 min in PBS containing 4% (v/v) p-formal-
dehyde (PBS-PFA). Parasites were blocked for 30 min in 5% (w/v) Bovine Serum Albumin
(Sigma) in PBS (PBS-A) supplemented with 0.5% (w/v) saponin (Sigma) for permeabilization,
and probed with the indicated antiserum diluted in PBS-A. After extensive washings with
PBS-A, secondary Alexa Fluor-conjugated antibodies (Molecular Probes) were added. Nuclei
were stained with DAPI prior to montage in FluorSave reagent (CalBiochem). To evaluate the
reactivity of T. cruzi intracellular stages 10,000 Vero cells were plated onto round coverslips,
let stand overnight and infected with 1 x 106 CL Brener trypomastigotes per coverslip as
described [35]. After 5 h, trypomastigotes were removed and cells were extensively washed
and incubated in DMEM 10% (v/v) SFB. At 72–120 h post-infection, cells were washed with
PBS, fixed and processed for IIF as above. Images were obtained with a Nikon Eclipse 80i epi-
fluorescence microscope coupled to a DS-Qi1 CCD camera, and processed using ImageJ. For
co-localization analyses, trypomastigotes fixed and adhered to cover-slips as above were
blocked with PBS supplemented with 3% (w/v) BSA and 2% (v/v) horse serum (PBS-AHS) and
incubated with rat anti-TolT-A and mouse anti-TolT-B sera (both diluted 1:100 in PBS-AHS).
Following extensive washes, secondary antibodies were added for 1 h at 1:1,000 dilution in
PBS-AHS. Images were obtained with an Olympus IX-81 microscope attached with a FV-1000
confocal module. Co-localization analysis was assessed using the Co-localization Finder plugin
from ImageJ.
TolT antigens in Trypanosoma cruzi
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Immunoprecipitation
CL Brener trypomastigotes (2 x 108) were resuspended in 1 ml of ip buffer (PBS supplemented
with 0.1% (v/v) Triton X-100 and a protease inhibitor cocktail (Sigma-Aldrich)). The extract
(input fraction) was added with 6 μl of TolT-A antiserum raised in rat and incubated overnight
at 4˚C under constant agitation. This mixture was then added with 150 μl of protein G-Sephar-
ose (GE Healthcare) previously washed with 500 μl of ip buffer, and incubated for 3 h at 4˚C
under constant agitation. The tube was centrifuged at 600 x g for 1 min. The supernatant
(flow-through fraction) was removed, resin washed five times in 1 ml each of ip buffer, and
stripped at 100˚C for 5 min in SDS-PAGE loading buffer: 50 mM Tris-HCl pH6.8, 1% (w/v)
SDS, 0.01% (w/v) bromophenol blue, 10% (v/v) glycerol and 50 mM dithiothreitol (DTT).
Gel electrophoresis and Western blots
To achieve non-reducing conditions, the reducing reagent (DTT) was omitted from the
SDS-PAGE loading buffer (see composition above). Samples were mixed with the indicated
loading buffer and heated at 100˚C for 3 min before being processed for Western blot as
described [14]. Briefly, extracts from 1.5 x 107 parasites were resolved into SDS-PAGE (12.5%
gels), transferred onto PVDF membranes (GE Healthcare), reacted with the indicated antise-
rum followed by HRP-conjugated secondary antibodies and developed using enhanced chemi-
luminescence (Thermo).
Purification of GPI-anchored proteins and phosphoinositol specific
phospholipase C (PI-PLC) treatment
Pellets containing 1–5 x 108 trypomastigotes were homogenized in 2 mL of GPI buffer [10 mM
Tris/HCl, pH 7.4, 150 mM NaCl, 2% (v/v) Triton X-114, 1 mM PMSF and 1% (v/v) protease
inhibitor cocktail (Sigma)] on ice for 1 h and centrifuged at 8,800 x g for 10 min at 0˚C as
described [36]. The supernatant (S1) was stored at −20˚C for 24 h. The pellet (P1) was washed
with 1 ml of buffer A (10 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.06% (v/v) Triton X-114 and
1 mM PMSF) and stored. S1 was thawed and submitted to phase separation at 37˚C for 10 min
followed by centrifugation at 3,000 x g for 3 min at room temperature. The upper phase (S2)
was collected and the detergent-rich phase was re-extracted with 1 ml of buffer A. The upper
phase (S3) was collected, and the detergent rich phase was extracted with 1 ml of buffer A,
homogenized, incubated for 30 min at 0˚C and centrifuged at 18,000 x g for 10 min at 0˚C.
The pellet (P2) was washed with 1 ml of buffer A and stored, whereas the supernatant (S4) was
submitted to a new phase separation. The upper phase (S5) was collected and the lower deter-
gent-rich phase, enriched in GPI-anchored proteins, was taken as the GPI fraction (GPI). For
PI-PLC treatment, 5 x 107 trypomastigotes were treated with or without 0.1U of recombinant
PI-PLC from Bacillus cereus (Thermo) for 30 min at 4˚C. Normal morphology and motility
was controlled by microscopic observation before and after the incubation time. Following
PI-PLC treatment, parasite pellets and supernatants were separated by centrifugation and frac-
tions were processed for Western blot.
Concanavalin A fractionation and endoglycosidase H treatment
Trypomastigote pellets (3 x 108) were homogenized in 500 μL of ConA buffer [50 mM Tris/
HCl, pH 7.4, 150 mM NaCl, 1% (v/v) Triton X-100, 0.1% (v/v) Nonidet P40, 0.1% (w/v)
sodium deoxycholate, 5 mM Cl2Ca, 5 mM Cl2Mg, 5 mM Cl2Mn, 1% (v/v) inhibitor protease
cocktail (Sigma), and 1 mM DTT] and processed as described [36]. After clarification, parasite
extract was fractionated overnight at 4˚C onto 100 μL of ConA–Sepharose (GE Healthcare),
TolT antigens in Trypanosoma cruzi
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and retained glycoproteins eluted with 50 μL of SDS-PAGE loading buffer. Flow-through and
ConA-bound fractions were analyzed by Western blot with different antisera. For N-glycosyla-
tion analysis, trypomastigotes were lysed in 1X Glycoprotein Denaturing Buffer (BioLabs),
boiled for 10 min and extracts corresponding to 2.5 x 107 parasites were treated with 2,000–
3,000U of Endoglycosidase H for 1 h following manufacturer’s procedures (BioLabs) and ana-
lyzed by Western blot.
Peptide microarrays
Synthesis, screening and data analysis of high-density T. cruzi-derived peptide microarrays
have been described [31,37].
Enzyme-linked Immunosorbent Assay (ELISA)
GST-fusion proteins were dissolved in carbonate buffer (pH 9.6) at 10 μg/mL. Flat-bottomed
96-well Nunc-Immuno plates (Nunc, Roskilde, Denmark) were coated overnight at 4˚C with
100 μL of the antigen solution, washed 3 times with PBS containing 0.05% (v/v) Tween 20
(PBS/T), and blocked for 1 h with 4% (w/v) skim milk in PBS/T at 37˚C [33]. The plates were
washed 3 times with PBS/T prior to the addition of serum samples diluted 1:500 in blocking
buffer. Following incubation for 1 h at 37˚C and washings with PBS/T, HRP-conjugated goat
IgG to species-specific IgG (all from Sigma) diluted 1:5,000 in blocking buffer was added to
the plates, and incubated at 37˚C for 1 h. The plates were next washed and incubated with
100 μL of freshly prepared 0.5 mM 3,3’,5,5’-tetramethylbenzidine (Sigma) in citrate-phosphate
buffer (pH 4.2) containing 0.2% (v/v) hydrogen peroxide. The reaction was stopped with 50 μL
of 2 M sulfuric acid, and the absorbance at 450 nm was read. Each sample was assayed in tripli-
cate, unless otherwise indicated.
Fluorescence magnetic beads immunoassays (FMBIA)
Synthesis and coating of superparamagnetic microbeads with purified GST-fusion proteins
were performed as described [32]. Functionalized beads (0.5 μg of each antigen in 20 μL of
beads per reaction) were incubated with human serum samples (1:100 dilution), washed three
times and bound antibodies were detected with DyLight 650-conjugated goat anti-human IgG
antibodies (1:1,000 dilution, Jackson ImmunoResearch Laboratories). After washing three
times, fluorescence was directly determined using a plate fluorometer (DTX880 Multimode
Detector, Beckman Coulter). Incubation of coated beads with serum samples and conjugate
antibodies were carried out for 5 min each, at room temperature without agitation. Sample
and conjugate antibody dilutions, as well as washes between incubation steps were performed
with PBS containing 0.2% (v/v) Tween 20. Washes were done using a magnetic rack without
the need of centrifugation. Results of the FMBIA were expressed as percentage of reactivity of
the mean fluorescence units of a standardized, positive control serum included in each assay
run [32].
Study population
Serum samples from T. cruzi-infected subjects have been described [32,33,38], and were
obtained from the Laboratorio de Enfermedad de Chagas, Hospital de Ninos "Dr. Ricardo
Gutierrez". All procedures were approved by the research and teaching committee and the bio-
ethics committee of this institution, and followed the Declaration of Helsinki Principles. Writ-
ten informed consent was obtained from all individuals (or from their legal representatives),
and all samples were decoded and de-identified before they were provided for research
TolT antigens in Trypanosoma cruzi
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purposes. Chagasic patients were coursing the chronic stage of the disease without cardiac or
gastrointestinal compromise. Serum samples were analyzed for T. cruzi-specific antibodies
with the following commercially available kits: ELISA using total parasite homogenate (Wiener
lab, Argentina) and indirect hemmaglutination assay (IHA, Polychaco, Argentina). The partic-
ipating subjects currently live within the urban limits of Buenos Aires, an area free of vector-
borne parasite transmission, though they (or their parents) were born and raised in endemic
areas from Argentina or neighbor countries, where most likely acquired T. cruzi infection.
Serum samples from healthy individuals that gave negative results in the aforementioned tests
were obtained from different blood banks: Fundacio´n Hemocentro Buenos Aires (Buenos
Aires, Argentina), Hospital de Enfermedades Infecciosas ‘Dr. Francisco Javier Muñiz’ (Buenos
Aires, Argentina), Hospital Italiano de Buenos Aires (Buenos Aires, Argentina) and Hospital
Municipal ‘Dr. Diego E. Thompson’ (San Martı´n, Buenos Aires, Argentina).
Ethics statement
The Institutional Review Board of UNSAM has evaluated the current project and considered
that it complies with the Basic HHS Policy for Protection of Human Research Subjects require-
ments to be included in the ‘exemption 4’, because it involved the use of de-coded and de-
identified human serum samples obtained from sera repositories. The protocol of animal
immunization followed in this study was approved by the Committee on the Ethics of Animal
Experiments of the Universidad Nacional de San Martı´n (IACUC/CICUAE N˚ 08/2015), and
all the procedures were carried out according with the recommendations of the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health.
Results
Identification and in silico characterization of TolT genes in
trypanosomatids
Searches in the kinetoplastid genomic databases at TriTrypDB and GeneDB were carried out
using the complete ORF of T. cruzi TolT1 as bait [11]. A total of 43 different sequences show-
ing significant similarity (> 40% nucleotide identity) to TolT1 were retrieved; 38 sequences
from different isolates of T. cruzi (CL Brener, Sylvio X-10, Dm28c, Esmeraldo) and 5
sequences from phylogenetically related protozoa such as the bat parasite T. cruzi marinkellei
(4 sequences) and the human parasite Trypanosoma rangeli (1 sequence). Further searches
were carried out using different TolT deduced protein sequences as query, which allowed for
the identification of an additional TolT molecule in the reptilian parasite Trypanosoma grayi
(DQ04_05721021). No TolT-related sequence was found in the genus Leishmania or in strict
salivarian trypanosomes, i.e. trypanosomes that develop in the salivary glands of the insect vec-
tor such as Trypanosoma brucei, Trypanosoma congolense, Trypanosoma evansi and Trypano-
soma vivax. A phylogenetic tree based on Neighbor-Joining method allowed the definition of
3 main groups of TolT-related sequences (termed TolT-A, -B and -C), which were supported
by significant bootstrap values (Fig 1).
TolT-A sequences showed ~96–100% identity to TolT1 and included the 3 original
sequences from the T. cruzi Esmeraldo strain [11], 5 full-length sequences from the T. cruzi CL
Brener clone (TcCLB.508767.20, TcCLB.506617.10, TcCLB.506617.20, TcCLB.504157.130 and
TcCLB.511109.10) and one partial sequence, also from CL Brener (TcCLB.506617.5) bearing
C-terminal truncation (Fig 1). As originally described in the Esmeraldo strain [11], TolT-A
sequences in CL Brener were arranged in a head-to-tail assembly of 3 members, which mapped
to chromosome 23 (Fig 2). A fourth gene, TcCLB.504157.130, could not be linked to this
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cluster most likely due to CL Brener genome assembly deficiencies. Similar analyses performed
on T. cruzi TCC, a hybrid strain from the same evolutionary lineage than CL Brener with a
high-quality genome assembly [26], strongly supported the inclusion of TcCLB.504157.130
within the CL Brener TolT-A cluster found in chromosome 23. Moreover, they suggested the
existence of additional TolT-A members in such CL Brener cluster that may have collapsed
during genome assembly (Fig 2). TcCLB.511109.10 was annotated as a pseudogene due to a
single nucleotide deletion that originated a frame shift mutation within the deduced N-termi-
nal signal peptide (S1 Fig). Downstream from this mutation, however, TcCLB.511109.10
sequence was > 96% identical to the remaining TolT-A genes (S1 Fig), suggesting that it con-
stitutes either a very recent pseudogene or, most likely, a sequencing error. Indeed, the ortho-
logous TCC gene (tcc_111_157, Fig 2) was 100% identical to TcCLB.511109.10 except for this
Fig 1. Evolutionary relationship of TolT genes in trypanosomatids. An unrooted phylogenetic tree was constructed
from nucleotide alignments using the Neighbor-Joining method and bootstrapped using 1,000 permutations.
Bootstrap support values> 70 are indicated by dots. The scale indicates the nucleotide substitution distance along the
branches. Sections of the tree are colorized according to the TolT group to which they belong. Genes that cannot be
included in any cluster and pseudogenes are indicated with red letters and asterisks, respectively. Abbreviations:
TcCLB, T. cruzi CL Brener; TcSYL or TcSYLVIO, T. cruzi Sylvio X-10; TCDM or BCY84, T. cruzi Dm28c; Tc_MARK,
T. cruzi marinkellei; TRSC, Trypanosoma rangeli SC58.
https://doi.org/10.1371/journal.pntd.0007245.g001
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single nucleotide deletion. The TolT-A group also included 5 sequences from T. cruzi Dm28c,
1 from T. cruzi Silvio X-10 and 2 from T. cruzi marinkellei (Fig 1).
The TolT-B group displayed 76–90% identity to TolT1 and comprised 2 full-length
sequences (TcCLB.510433.20 and TcCLB.504277.20) and 2 partial sequences bearing N-termi-
nal truncations (TcCLB.504277.11 and TcCLB.508767.10) in the CL Brener genome (Fig 2).
TolT-B sequences mapped to a single cluster present in chromosome 35 except for
TcCLB.508767.10, which localized immediately downstream to TcCLB.508767.20 within the
‘Esmeraldo’ haplotype of the TolT-A genomic cluster (Fig 2). The TCC genome supported this
particular disposition and, again, suggested the existence of additional TolT-B genes in the CL
Brener chromosome 35 cluster (Fig 2). TolT-B also included 5 sequences from T. cruzi Sylvio
X-10 and 7 sequences from T. cruzi Dm28c (Fig 1). Interestingly, TcCLB.510433.20 and
TcCLB.504277.20 were almost identical sequences except for their predicted C-termini, where
they become highly divergent at both nucleotide and amino acid sequences (S2 Fig). Because
of these differences, the TcCLB.504277.20 deduced protein was predicted to lose the GPI-
anchoring signal. The identification of orthologous genes in Sylvio X-10 (TcSYL_004013) and
TCC (tcc_94_104) strongly argued that ‘GPI-less’ variants are not the result of genome assem-
bly problems but rather genuinely diversified TolT molecules (S2 Fig).
The TolT-C group was composed by just two alleles of a single gene (TcCLB.504277.30 and
TcCLB.506815.20) within the CL Brener genome (Fig 2). This locus mapped immediately
downstream of the TolT-B genomic cluster present in chromosome 35; and a quite similar dis-
position was also observed in TCC (Fig 2). TcCLB.506815.20 was annotated as a MASP pseu-
dogene. However, manual inspection allowed us to identify a partial TolT-B gene, a putative
intergenic region and a complete TolT-C gene within this sequence (Fig 2 and S3 Fig). The
Fig 2. Genomic organization of TolT genes in T. cruzi CL Brener and TCC strains. Schematic representation of T.
cruzi CL Brener (above) and TCC (below) genomic scaffolds containing TolT sequences. Vertical lines denote contig
breaks in the CL Brener genome, and green and blue striped regions in TcCLB.506815.20 indicate sequences bearing
high similarity to TcCLB.504277.20 and TcCLB.504277.30, respectively. Orthologous sequences (100% nucleotide
identity) are connected by dotted lines. Abbreviations: TcChr-S and -P, ‘Esmeraldo’ and ‘non-Esmeraldo’ haplotype,
respectively, of the hybrid CL Brener clone. Genes are colorized according to the TolT group to which they belong, as
defined in Fig 1.
https://doi.org/10.1371/journal.pntd.0007245.g002
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TolT-C group also included sequences retrieved from T. cruzi Dm28c, T. cruzi Sylvio X-10
and T. cruzi marinkellei (Fig 1).
TolT proteins in T. cruzi
The main proteins encoded by TolT-A, TolT-B and TolT-C bore 310, 305/284 and 344 amino
acids, respectively, with predicted molecular masses of ~30.9–37.1 kDa and predicted pI of
7.1–8.2. All of them displayed sequences that constitute canonical signatures of surface locali-
zation and/or secretion, including a predicted N-terminal signal peptide (SP) and a C-terminal
GPI-anchoring signal (except for the ‘GPI-less’ TcCLB.504277.20) (Fig 3A). In addition, differ-
ent algorithms predicted the existence of palmitoylation signals in TolT-A and TolT-B ‘canon-
ical’ proteins (Fig 3A). The deduced TolT polypeptides were characterized by a high content of
Ala (18.8 to 24.4%), Glu (9.0 to 11.9%), Leu (8.1 to 9.9%), Lys (6.3 to 10.4%) and Arg (4.9 to
8.1%), with these residues not evenly distributed throughout the entire proteins (Fig 3A). In
addition, TolT-A and TolT-B products displayed a Cys-X7-Cys3 motif (where X means any
residue) in their predicted SP (Fig 3A). Interestingly, this motif is also present in the SP of T.
cruzi mammal-dwelling-expressed mucins (TcMUC, [28,39]), suggesting that TcMUC and
TolT molecules may have a common origin or, more likely, that this motif may have been
selected for the improved expression and/or post-translational processing of surface-associated
molecules in such parasite forms (see below).
The predicted mature TolT molecules, i.e. upon processing of the SP and, if present, the
GPI-anchoring signal displayed 17–41 potential sites for phosphorylation, 2–5 sites for N-gly-
cosylation, 27–36 sites for O-glycosylation, and 2 strictly conserved Cys residues (Fig 3A). The
only recognizable and unifying feature was the presence of two Ala-rich regions, which are
predicted to fold into an αhelix-enriched secondary structure (Fig 3A). These regions, along
with the interconnecting sequence, displayed structural and marginal sequence similarity to
the central domain of bacterial TolA proteins. TolT-A and TolT-B products, in addition, bore
a particular region towards the mature C-terminus, which is highly enriched in Arg and Glu
residues (Fig 3A).
Amino acid alignments highlighted very few and minor intra-group polymorphisms
among CL Brener TolT proteins, the only exception being the C-terminus of the ‘GPI-less’ var-
iant encoded by TcCLB.504277.20 (S4 Fig). When comparing between groups, the genetic
drift of TolT-C proteins and the high level of sequence conservation among TolT-A and
TolT-B members were also evident (S4 Fig). Regarding the latter issue, it is worth noting that
the amino acid identity value between TolT-A and ‘canonical’ TolT-B deduced products was
not homogeneous. Rather, and as schematized in Fig 3B, this value was maximal along their
predicted SP and C-terminal region but dropped down significantly towards their predicted
mature N-terminal region (from residues ~40 to 180).
Expression of TolT RNAs and proteins during the T. cruzi life-cycle
Samples of total RNA from different T. cruzi CL Brener developmental forms were purified
and the relative expression of representative members of each TolT group evaluated by RT-
qPCR. As shown in Fig 4, TolT-A transcripts were the most abundant, followed by TolT-B and
TolT-C. Abundance of TolT mRNAs was significantly decreased in epimastigotes, particularly
for TolT-C, for which transcript expression was barely detectable (Fig 4). When comparing
between mammal-dwelling stages, i.e. trypomastigotes vs amastigotes, and somehow at odds
with early steady-state transcriptome analyses [40], no significant differences were observed
for either TolT group (Fig 4).
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We next produced antisera against recombinant, GST-fusion proteins spanning sequences
of different TolT molecules (S2 Table). To minimize the extent of possible cross-recognition
between TolT-A and TolT-B molecules, specific antisera were raised against sequences from
their most divergent, mature N-terminal regions (Fig 3). We also generated an antiserum to
Fig 3. Diversity of TolT products in T. cruzi. A) Schematic illustration of predicted TolT products. For TolT-B, one
‘canonical’ and one ‘GPI-less’ variants are shown. The predicted signal peptide (SP) and GPI-anchoring sequences
(GPI) are indicated in grey. Alanine (A)-rich domains and the arginine (R)/glutamic acid (E)-rich motif are denoted
as yellow and red boxes, respectively. N-glycosylation sequons are indicated as pins. Conserved cysteine residues
are shown, and those predicted to undergo palmitoylation are colored blue. B) Multiple alignments results of
TolT-A (TcCLB.508767.20, TcCLB.506617.10, TcCLB.506617.20 and TcCLB.504157.130) and ‘canonical’ TolT-B
(TcCLB.504277.20 and TcCLB.510433.20) protein sequences are depicted as WebLogo graphics. Residues from TolT-A
or TolT-B sequences are indicated by red and green letters, respectively, whereas residues conserved between both
groups are indicated in black letters.
https://doi.org/10.1371/journal.pntd.0007245.g003
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the TolT-A and TolT-B conserved C-terminal region (henceforth TolTA/B antiserum, S2
Table). As for the most divergent TolT-C group, we generated an antiserum towards a GST-
fusion protein spanning most of its central region (S2 Table). These antisera were used to
determine expression of TolT products along the parasite life cycle. IIF assays on T. cruzi-
infected cells indicated that TolT-A and particularly TolT-B variants were significantly more
expressed in trypomastigotes as compared to amastigotes (Fig 5A). The TolT-C antiserum, on
the other hand, yielded similar signals in both parasite stages (Fig 5A). TolT-C signals, in turn,
were weaker than those recorded for TolT-A and TolT-B, and should be thus compensated for
presentation.
As originally reported for ‘TolT’ [9], TolT-A, TolT-B and TolT-C molecules localized to the
part of the flagellum in contact with the parasite body. This was verified in both intracellular
and extracellular trypomastigotes (Fig 5A and 5B). It is however worth noting that TolT-C
molecules displayed an apparent continuous distribution whereas TolT-A and TolT-B proteins
yielded a more punctuated labeling pattern (Fig 5B). Confocal images strongly supported
TolT-A and TolT-B discontinuous distribution (Fig 5C). Most importantly, they revealed only
minor co-localization between TolT-A and TolT-B signals (Fig 5C; Pearson’s R correlation
coefficient of co-localization = -0.3).
Fig 4. Expression analysis of TolT mRNAs in T. cruzi. mRNA expression profile of different TolT groups on major
developmental stages of T. cruzi CL Brener. Asterisks denote significant differences between the population means
(P< 0.05) assessed by two-way ANOVA test after Bonferroni’s correction. A, amastigote; T, trypomastigote; E,
epimastigote.
https://doi.org/10.1371/journal.pntd.0007245.g004
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Fig 5. Expression analysis of TolT products in T. cruzi. A and B) T. cruzi-infected HeLa cells (A) or purified
trypomastigotes (B) were permeabilized and analyzed by indirect immunofluorescence (IIF) assays using the indicated
antiserum. DAPI signals are shown in blue. Enlarged regions are depicted with squares in the original merge images.
In the lower panels, a schematic drawing of amastigote forms in which the nucleus (n), the kinetoplastid DNA (k) and
the vestigial flagellum (vf) are indicated. Arrowheads point to observed TolT signals. C) Co-localization analyses.
Representative confocal image of trypomastigote processed for IIF using rat TolT-A antiserum (in green) and mouse
TolT-B antiserum (in red). Arrowheads point to co-localizing signals. D) Total extracts of different parasite stages (A,
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In addition to the trypomastigote flagellum, some TolT-A antisera (but not all of them) also
labeled a discrete region towards the posterior end, i.e. the parasite pole opposed to the site of
emergence of the (vestigial) flagellum of amastigote forms (Fig 5A). This was consistent with
Western blot data, showing the presence of TolT-A-reactive species, though in significantly
lesser amounts as compared to trypomastigote ones, in amastigote forms (Fig 5D). Interest-
ingly amastigote- and trypomastigote-expressed TolT-A molecules displayed different electro-
phoretic mobility, suggesting differences in their post-translational processing (Fig 5D).
TolT-B and TolT-C antisera also labeled discrete internal region(s) of amastigote forms by IIF
assays (Fig 5A). At variance with TolT-A, TolT-B signals accumulated towards the anterior
pole of the amastigote whereas TolT-C products accumulated at both amastigote tips, and also
at a compartment juxtaposed to the kinetoplast DNA (kDNA, Fig 5A). Amastigote-expressed
TolT-B and TolT-C species could not be detected by Western blot (Fig 5D), most likely due to
differences in the sensitivity of both methods. Neither antiserum displayed specific reactivity
towards epimastigote stages (Fig 5D). Immunoprecipitation assays further demonstrated that
the generated antisera were TolT group specific (Fig 5E).
Biochemical features of TolT proteins
To evaluate in silico predictions (Fig 3A), intact CL Brener trypomastigotes were firstly treated
with PI-PLC, which specifically cleaves T. cruzi GPI anchors, and the supernatant and pellet
fractions were analyzed by Western blot. As shown in Fig 6A, addition of PI-PLC caused the
disappearance of TolT-A-, TolT-B- and TolT-C-reactive bands from the parasite pellets, and
their concomitant appearance in the supernatant fractions. Interestingly, a minor fraction of
TolT-A and TolT-C, but not TolT-B molecules could not be solubilized by PI-PLC (Fig 6A).
These PI-PLC-resistant species may bear a different kind of acyl group or, alternatively, they
may correspond to immature molecules that have not yet reached the parasite surface.
We next purified total GPI-anchored proteins from CL Brener trypomastigotes taking
advantage of their preferential fractionation in Triton X-114. Aliquots corresponding to the
different fractions were analyzed by Western blot. As shown in Fig 6B, TolT-A and TolT-B
species were found in P1 (total parasite lysates), P2 (containing mostly membrane-associated
molecules excluded from GPI- and sterol-rich micro-domains), and GPI fractions (containing
mostly GPI-anchored proteins). Together with PI-PLC data, these findings confirmed that
TolT molecules (at least a major fraction of them) are anchored to the trypomastigote plasma
membrane through a GPI lipid motif. The finding of TolT-A and TolT-C PI-PLC-resistant
species (Fig 6A), and of inter-group variations in the GPI/P2 abundance ratio (Fig 6B)
unveiled certain heterogeneity in the way TolT molecules become associated to the parasite
surface, and suggest that a minor fraction of them, particularly from TolT-A and TolT-C
groups, use a different acyl group to achieve this issue.
We also analyzed whether the consensus N-glycosylation sites predicted in the deduced
TolT products (Fig 3A) had an attached oligosaccharide in vivo. To that end, we initially car-
ried out Western blot assays of CL Brener trypomastigote lysates upon fractionation on ConA
lectin. As shown in Fig 6C, part of TolT-A-, TolT-B and TolT-C-reactive products were recov-
ered in the ConA-bound fractions, indicating that at least a fraction of them indeed bear high-
amastigote; T, trypomastigote; E, epimastigote) were probed with the indicated antiserum by Western blotting.
Molecular markers (in kDa) are indicated. E) Total extracts of purified trypomastigotes were immunoprecipitated
using rat TolT-A antiserum and input, flow-through (FT) and immunoprecipitated (IP) fractions were analyzed by
Western blot using the indicated mouse antiserum. All of the parasites shown in this figure were from CL Brener
strain.
https://doi.org/10.1371/journal.pntd.0007245.g005
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Fig 6. Biochemical features of TolT products. A) Intact trypomastigotes were treated (+) or not (-) with B. cereus PI-PLC for 30
min. Parasites were centrifuged, and aliquots from supernatants (SN) and total parasite lysates (P) were probed with the indicated
antiserum. B) Trypomastigotes were fractionated with Triton X-114 and samples from each purification step (see Materials and
methods) were probed with the indicated antiserum. C) Trypomastigote extracts were fractionated onto ConA-sepharose and
aliquots of both flow-through (FT) and bound (B) fractions were probed with the indicated antiserum. D) Samples from
trypomastigote extracts were treated (+) or not (-) with endoglycosidase H and probed with the indicated antiserum. E) Samples
from trypomastigote extracts were resolved by SDS-PAGE under reducing (DTT +) and non-reducing (DTT -) conditions and
probed with the indicated antiserum. F) Schematic illustration of a ‘canonical’ TolT-B protein showing the predicted signal peptide
(SP), the GPI-anchoring signal (GPI) and the conserved cysteine residues (C75 and C127). Sequences derived from this protein were
expressed as GST-fusion molecules and the residues spanned by each construct are shown below (numbers indicate amino acid
positions relative to the initial methionine). Samples (3 μg) from the indicated GST-TolT-B fusion proteins were resolved by
SDS-PAGE under reducing (DTT +) and non-reducing (DTT -) conditions and stained by Coomasie Brilliant Blue. In E) and F),
arrowheads indicate the position of oligomeric species. Molecular markers (in kDa) are indicated.
https://doi.org/10.1371/journal.pntd.0007245.g006
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mannose type glycans. Trypomastigote lysates were next treated with endoglycosidase H. In
line with original ‘TolT’ results [9], this treatment increased the electrophoretic mobility of
TolT-A and TolT-B molecules (Fig 6D). Interestingly, the lower TolT-A-reactive band was not
affected by endoglycosidase H treatment, suggesting that it may correspond to non-glycosy-
lated species. Together with ConA-fractionation data, these findings suggest that at least part
of the species from each TolT group undergo N-glycosylation in vivo.
To explore a possible structural role of Cys residues on the mature region of TolT molecules
(Fig 3A), trypomastigote extracts were resolved in parallel on reducing and non-reducing
SDS-PAGE and evaluated by Western blot. As shown, TolT-B molecules appeared to assemble
into oligomers, which translated into the appearance of ~100 kDa species in non-reducing
SDS-PAGE (Fig 6E). Considering the apparent molecular mass of TolT-B monomers (~35
kDa), the ~100 kDa species may likely correspond to trimers. In sharp contrast, solely mono-
meric species were observed for TolT-A and TolT-C molecules under non-reducing condi-
tions (Fig 6E). TSSA, a well-characterized GPI-anchored molecule from the trypomastigote
surface and devoid of Cys residues on its mature region [35,41] was used as control for these
assays, and yielded solely monomeric species (Fig 6E). As expected, the ~100 kDa band was
also revealed by the TolTA/B antiserum (Fig 6E). However, and since this antiserum recog-
nized both TolTA (exclusively monomeric) and TolT-B (mostly trimeric), the ratio between
trimers/monomers was shifted towards monomers (Fig 6E).
When expressed in a bacterial system, a TolT-B fusion molecule bearing both Cys residues
75 and 127 (GST-TolT-B 61–162) was able to assemble into multiple oligomeric forms (Fig
6F). GST-TolTB 97–162 (bearing solely Cys 127), on the other hand, yielded monomeric spe-
cies and low amounts of a ~70 kDa species, likely a dimer, suggesting that the participation of
both Cys residues is a pre-requisite in order to get trimeric and/or higher order aggregates.
GST-TolT-B 61–103 (bearing solely Cys 75) was not able to dimerize under non-reducing
conditions (Fig 6F), similar to GST-TolT-B 155–260 (bearing no Cys residue) used as nega-
tive control. These findings indicated that Cys 75 residue in GST-TolT-B 61–103 cannot
engage into disulfide bond formation, likely due to structural constraints. Accordingly, in
vitro incubation of GST-TolT-B 97–162 alone or in combination with GST-TolT-B 61–103
yielded the same profiling of high molecular mass species, i.e. solely the ~70 kDa band corre-
sponding to the dimeric form of GST-TolT-B 97–162 (Fig 6F). Together, these findings
strongly suggest i) that TolT-B, but neither TolT-A nor TolT-C molecules, are spontaneously
assembled into trimers in vivo, on the surface of the trypomastigote; and ii) that trimeric
TolT-B species are sustained by covalent inter-molecular disulfide bonds involving both Cys
127 and Cys 75.
TolT antibody recognition is focused to the mature, C-terminal regions of
TolT-A and TolT-B members
TolT molecules were shown to elicit B-cell responses during T. cruzi infection in humans,
and 3 full-length variants (2 ‘canonical’ TolT-B and 1 TolT-A member) were thereby
included in a 16-recombinant protein-based, multiplexed assay for serodiagnosis of Chagas
disease [42]. However, neither the fine antigenic structure of TolT molecules nor the impact
of herein evidenced diversity on the TolT epitopic landscape was yet addressed. Three
TolT-A (TcCLB.506617.10, TcCLB.504157.130 and TcCLB.508767.20), 2 ‘canonical’ TolT-B
(TcCLB.510433.20 and TcCLB.504277.11), 1 ‘GPI-less’ TolT-B (TcCLB.504277.20), and 1
TolT-C (TcCLB.504277.30) sequences were firstly analyzed using high-density peptide
microarrays [37]. Briefly, overlapping sequences with 1-amino acid residue offset were
probed with IgG samples from different pools of chronic Chagasic sera. Arrays were
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processed firstly with normal human IgG to assess the background reactivity, and final anti-
genic profiles calculated by subtraction [37].
Oddly, TolT products displayed an overall very low reactivity when assessed by this
approach. As shown in Fig 7A, solely TcCLB.504277.30 (TolT-C), TcCLB.504277.11 (‘canoni-
cal’ TolT-B) and TcCLB.508767.20 (TolT-A) could be annotated as ‘weak antigens’ in the con-
text of the whole array (see also [37]). Moreover, each one of them actually displayed a single
‘antigenic peak’, i.e. a stretch of consecutive peptides yielding reactivities above the established
cutoff (Fig 7A). The TolT-C antigenic peak encompassed the sequence 145AAVDADTAA-
LAALLEVLQ, and was recognized by 2 out of 3 analyzed pools of sera (Fig 7A). In addition,
TolT-C yielded a couple of negative antigenic peaks in one assay, suggesting that these
sequences may be recognized by IgGs from healthy individuals (Fig 7A) [37]. TolT-A and
TolT-B weak antigenic peaks encompassed the same sequence (TATRIQRTRPRVD), located
on their C-terminal region, which was recognized by solely 1 analyzed pool of sera (Fig 7A).
Large variations in the length of TcCLB.504277.11 and TcCLB.508767.20 deduced proteins,
and hence in the relative location of the TATRIQRTRPRVD epitope within them, reflected
that TcCLB.504277.11 was annotated as an N-terminal truncated protein (see Fig 2).
The antigenic profile of TolT proteins was next evaluated using recombinant proteins. To
that end, a series of GST-fusion molecules were generated and purified from engineered bacte-
ria. These molecules were used in ELISA tests to search for specific antibodies in serum sam-
ples from chronic Chagasic patients. As shown in Fig 7B, TolT-specific antibodies were indeed
detected by this procedure in a fraction of assayed Chagasic sera and in none of the 19 normal
serum samples (Fig 7B). Every TolT-positive serum recognized the C-terminal region con-
served among TolT-A and TolT-B molecules (GST-TolT-B/A C-term protein, Fig 7B). Due to
cloning/expression purposes, the TATRIQRTRPRVD sequence highlighted on the microarray
assays (Fig 7A) was not included in the GST-TolT-B/A C-term protein, hence indicating the
presence of additional B-cell epitope(s) in this molecule. In addition to the GST-TolT-B/A C-
term protein, solely one sample reacted against the N-terminal region of TolT-A and two sam-
ples against TolT-C (Fig 7B). Western blot assays to a panel of TolT-B deletion mutants further
stressed the significantly skewed recognition profile of anti-TolT antibodies elicited during T.
cruzi infection in humans. As shown in Fig 7C, the recognition of four TolT-reactive Chagasic
sera not included in our ELISA panel was also restricted to the conserved C-terminal region
(residues 155–260, according to TolT-B). Quite similar results were obtained upon testing
serum samples from T. cruzi-infected mice, rabbits and dogs by ELISA (Fig 7B).
The diagnostic performance of a GST-TolT-B fusion protein spanning most of its mature
region (residues Q61 to R260, S2 Table) was evaluated by a recently developed FMBIA test,
using 2 panels of serum samples obtained from non-infected individuals (n = 122) or from
patients with chronic Chagas disease (n = 78). The latter was heterogeneous, and included peo-
ple living and/or raised in different endemic areas from Argentina or neighbor countries, and
hence most probably parasitized by different T. cruzi strains [43]. For comparison purposes,
the same analysis was performed in parallel using GST-Ag1, a well-established Chagas disease
serodiagnostic reagent [27]. For both antigens, a significant difference in the overall reactivity
values between the negative and positive populations was obtained (P< 0.0001; Fig 8A). Most
importanly, the area under the ROC curve for GST-TolT-B showed that this is a highly perfor-
mant diagnostic classifier, with an area under the curve (AUC) value very similar to that of
GST-Ag1 (0.9430; 95% CI, 0.9089–0.9772 for GST-TolT-B and 0.9742, 95% CI, 0.9477–1 for
GST-Ag1) (Fig 8B). Plots of the diagnostic sensitivity and specificity of these assays as a func-
tion of the cut-off values (TG-ROCplot) indicated a cut-off value that concurrently optimizes
both parameters of 17.4% for Ag1 and of 39.8% for GST-TolT-B. Overall, these results indicate
that a recombinant, GST-fusion protein spanning most of the mature region of a ‘canonical’
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Fig 7. Antibody binding to TolT peptides is focused to the conserved, mature C-terminal region of TolT-A and TolT-B
products. A) Microarrays composed of 15mer peptides overlapping by 14 residues spanning the deduced sequence of TolT
members were probed, in duplicate, with three IgG samples purified from different pools of chronic Chagasic sera (denoted as A, B
and C). The mean reactivity from each IgG sample toward every peptide (in arbitrary units of fluorescence) vs amino acid position
(taking as residue 1 the predicted initial Meth residue, except for TcCLB.504277.11) is indicated. Solely those TolT molecules
yielding positive results in at least one assay (see text and ref [37] for details) are shown. B) Dot plot analysis of ELISA results using
different GST-TolT fusion proteins: TolT-A F54-T174 (GST-TolT-A N-term), TolT-B Q61-L162 (GST-TolT-B N-term), TolT-B
G155-R260 (GST-TolT-B/A C-term), TolT-C A83 to D313 (GST-TolT-C) and GST. The sequences that were expressed as GST-
fusion molecules and the residues spanned by each construct (numbers indicate amino acid positions relative to the initial
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TolT-B molecule, including its antigenic and conserved C-terminus, provides an appealing
reagent for Chagas disease serodiagnosis.
Discussion
Despite original proposals [9,11], we herein show that TolT constitutes a complex family of
genes in kinetoplastids. According to phylogenomic data, it is apparently restricted to the
branch of stercorarian trypanosomes, i.e. trypanosomes that develop in the hindgut of the
insect vector, such as T. cruzi, T. cruzi marinkellei, T. grayi and T. rangeli. Even though T. ran-
geli is also able to develop in the triatomine salivary glands, taxonomic studies indicated it
failed to group with other strict salivarian trypanosomes [44]. Solely in the T. cruzi CL Brener
reference clone, we were able to find 12 TolT genes distributed in two chromosome clusters.
Moreover, comparative analyses carried out in TCC, a closely related strain with a better-qual-
ity genome assembly and annotation [26], strongly suggest that such TolT gene dosage may be
an underestimation. T. cruzi TolT genomic clusters comprise a discrete number of tandemly
arranged genes from the same group, i.e. TolT-A genes in chromosome 23 cluster and TolT-B
genes in chromosome 35 cluster. Within each cluster, TolT genes show minor polymorphisms
among them. As extensively discussed, gene expansion by tandem duplication without further
differentiation likely constitutes a kinetoplastid evolutionary strategy to increase protein yield
in the absence of transcriptional regulation [45]. Indeed, mRNA and protein expression data
roughly correlate with the estimated gene dosage for each TolT group. Interestingly, an addi-
tional and ‘different’ TolT gene is found immediately downstream of both TolT clusters,
strongly suggesting that it evolved by mutation accumulation on a previously duplicated copy
from another group. In the case of TolT-C genes, which display rather low similarity to the
remaining T. cruzi TolT genes (~47% identity to any TolT-A gene), this particular genomic dis-
position was one pivotal criterion for their inclusion within the TolT family.
Overall, the most parsimonious hypothesis integrating these findings suggests that TolT
emerged in an ancestor from trypanosomes, early after the divergence of the salivarian branch
[46]. The acquisition of its embedded bacterial TolA-like motif may have occurred either by
horizontal gene transfer, as previously proposed for other trypanosomatid molecules [47,48]
or by convergent evolution. Whatever the case, the original TolT sequence likely underwent
subsequent events of gene duplication followed (or not) by diversification (and eventually
pseudogenization), thus leading to the formation of a rather complex family of genes. A rather
similar evolutionary path, characterized by remarkable expansion and diversification, seems to
have been followed by several T. cruzi gene families coding for surface molecules involved in
the interaction with the mammalian and/or vector hosts [49].
TolT deduced proteins show a biased amino acid composition and molecular signatures of
surface localization and/or secretion such as cleavable SP, glycosylation, and lipid modifica-
tion. Based on topology predictions and experimental data, it could be inferred that, upon mat-
uration in the secretory pathway, TolT molecules become tethered to the outer leaflet of the
flagellar membrane via their C-termini. TolT membrane anchor most likely occurs post-trans-
lationally, by the addition of a GPI lipid moiety early upon their entry to the secretory pathway
methionine) are indicated. The ELISA plates were coated with the indicated antigen and incubated with 31 serum samples from
chronic Chagas-positive individuals (+) or 19 non-infected individuals (-). T. cruzi-infected dogs (n = 9), rabbits (n = 9) and mice
(n = 8) were also tested along with 2 non-infected individuals from the same species. The median and SD for each group are
indicated by box and whiskers. Asterisks denote significant differences between the population medians (P< 0.0001 for humans and
P< 0.05 for mice and rabbits, Mann-Whitney test). C) Aliquots (1 μg) of the indicated GST-TolT-B fusion proteins were stained by
Coomasie Brilliant blue (left panel) or probed with 4 different chronic Chagasic sera by Western blotting.
https://doi.org/10.1371/journal.pntd.0007245.g007
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[50]. However, and as mentioned, our data is compatible with the possibility that a minor frac-
tion of them, particularly those from TolT-A and TolT-C groups, use an alternative acyl group
(i.e. palmitoyl) to achieve this issue. The only exception to the topological model proposed
above would be TcCLB.504277.20, which loses its predicted GPI-anchoring signal due to
Fig 8. TolT-B constitutes an appealing candidate for Chagas disease serodiagnosis. A) Dot plot analysis. Positive
(POS) and negative (NEG) serum samples were tested with the fluorescence magnetic beads immunoassay using
microbeads functionalized with GST-Ag1 or GST-TolT-B Q61 to R260 proteins (see Materials and methods for
details). The mean and standard deviation for each group are indicated (GST-Ag1: POS, 68.0 ± 37.5; NEG, 10.9 ± 3.6.
GST-TolT-B: POS, 70.7 ± 28.9; NEG, 27.0 ± 10.2). ���, P< 0.0001; Mann-Whitney test. B) ROC curve analyses were
carried out using as reference samples the POS and NEG groups included in the dotplot analyses. AUC, area under the
ROC curve; values in parentheses indicate the 95% confidence interval. C) TG-ROC plot of the results. The dashed
lines indicate the cut-off values for which maximal diagnostic sensitivity (Se) or specificity (Sp) were achieved (8.3 and
31.2% for Ag1, and 19.5 and 61.3 for TolT). These two cut-off values represent the bounds of an intermediate range of
reactivity values (shaded areas). The dotted lines indicate the cut-off value that concurrently optimizes the Se and Sp
(17.4% for Ag1 and 39.8% for TolT).
https://doi.org/10.1371/journal.pntd.0007245.g008
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focalized mutation accumulation. As shown for T. cruzi surface mucins, recombinant GPI-
less variants (i.e. deletion mutants lacking the GPI-anchoring signal) accumulate in the endo-
plasmic reticulum, with only a minor fraction being ultimately released to the medium as
anchorless products [51]. Further studies, currently underway, will be required to address
TcCLB.504277.20 biochemical properties and sub-cellular distribution.
A unique and unifying feature of TolT molecules is that they bear similarity to the central
region of TolA proteins. These are integral membrane molecules dedicated to maintain outer
membrane stability in different bacteria such as Escherichia coli and Pseudomonas aeruginosa
[10,52,53], being used also for the uptake of several filamentous phages and bacterial toxins
called colicins [54]. TolA molecules are anchored to the inner bacterial membrane via their N-
terminal domain, and display a central region made up essentially of alanine-rich stretches
that show very stable helix conformation. Importantly, the TolA alanine-rich central region
seems to play mainly a structural role, allowing the projection of the functional C-terminal
region across the bacterial periplasm [54]. Though not experimentally proven, different algo-
rithms predict that the TolA-like motif present in T. cruzi TolT molecules also encompasses a
very long and unique αhelix, which likely adopts a rod-like structure on the trypomastigote
membrane. In such a case, the acquisition of the TolA-like motif on the TolT central region
may have been selected for as a crafty strategy to ensure the protrusion, and hence maximize
the exposition, of the outermost (and variable) mature N-terminal region. Variations on this
theme, leading to the projection of functional domains across the parasite glycocalix have been
proposed for other T. cruzi surface molecules [8,55,56]. Most importantly, the overall topologi-
cal model predicts a functional role for the TolT mature N-terminal regions; which according
to their sub-cellular distribution may be related to the interaction between the flagellum and
the trypomastigote body [57].
Original IIF assays carried out by Saborio et al showed that ‘TolT’ (presumably a TolT-A
molecule according to our current classification) localized to the trypomastigote flagellum sur-
face, apparently in the part of this structure in contact with the parasite body [9]. Here we
assessed this sub-cellular localization for every TolT product, suggesting that despite their
amino acid and biochemical variations all of them share the targeting signals responsible for
this selective trafficking. Most interestingly, TolT-A and TolT-B products distribute in discrete
foci along the surface of the trypomastigote flagellum. This is consistent with recent finding
showing a biased lipid composition for the flagellar membrane of trypanosomatids, which
apparently promotes the accumulation of GPI- and other kinds of acyl-anchored proteins into
lipid-raft-like structures [58]. Moreover, the punctuate and non-overlapping pattern observed
for TolT-A and TolT-B molecules builds upon our hypothesis of the trypomastigote mem-
brane as a highly organized structure made up of multiple and discrete nanoscale domains
bearing different protein composition [8,14]. Inter-molecular disulfide bonds leading to the
formation of TolT-B homopolymers may also contribute to the formation/organization of
these particular domains. Alternatively, disulfide bonds may have a rather classical structural
role as a TolT-B quality control system in the endoplasmic reticulum [59] or, as shown for
other protozoan surface antigens, in the undermining of the mammalian host immune
response [60]. In this sense, it should be emphasized the lack of antibody response to TolT N-
terminal regions. Our discoveries also raise the interesting possibility that the state of extracel-
lular reduction-oxidation reactions on the vicinity of the trypomastigote flagellum may regu-
late the polymerization status of TolT-B molecules in vivo, which in turn may affect their yet-
to-be-addressed functional and/or signaling properties [61–63]. In vivo studies using site-spe-
cific mutants and defined conditions should help to clarify these issues.
In addition to trypomastigotes, TolT products are also expressed on amastigote forms.
Most interestingly, amastigote-expressed molecules accumulate on intracellular
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compartments. TolT-A (and TolT-C) molecules accumulate in discrete regions towards the
posterior end of the amastigote, which may correspond to degradative organelles described
in T. cruzi insect-dwelling forms [64]. TolT-B (and TolT-C) molecules, on the other hand,
are likely retained in the flagellar pocket, the organelle that contributes to the traffic of GPI-
anchored proteins between the Golgi complex and the plasma membrane [65] whereas
TolT-C molecules accumulate in an undefined compartment juxtaposed to the kDNA.
Whether these intracellularly-displayed molecules correspond to immature proteins en
route to the amastigote membrane and/or to recycled species targeted for degradation
remains to be addressed.
Our immunological characterizations support TolT molecules as targets of the immune
response during T. cruzi infections. Indeed, by using a recently developed FMBIA test we
show that a recombinant, GST-fusion protein spanning most of the mature region of a ‘canon-
ical’ TolT-B molecule exhibits quite similar diagnostic performance than a well-established
T. cruzi antigen, included in commercial serodiagnostic tests [27]. Antibody recognition
seems to be focused towards peptides from the TolT-A/TolT-B conserved C-terminus, inde-
pendently of the evaluated mammalian species. These findings may be attributed to intrinsic
antigenic issues, i.e. biased distribution of B-cell epitopes, to the over-representation (in molar
terms) of the TolT conserved C-terminal region or to the in vivo molecular shielding of TolT
N-terminal regions by structural constraints and/or post-translational modifications. The lat-
ter hypothesis is however not consistent with IIF-based data showing that these regions are
readily available to antibodies on both trypomastigote and amastigote forms. The lack of corre-
lation between the peptide chip- and recombinant protein-based approaches, which is unique
among other tested T. cruzi molecules [31,33,37], suggest that B-cell epitopes from Tol-T mol-
ecules are not strictly linear in nature.
In summary, we have shown that TolT constitutes a complex family of genes in T. cruzi,
which could be split into three robust groups displaying differences in their structure, sub-cel-
lular distribution, post-translational modification and antigenic composition. The fact that
these molecules i) are abundantly expressed on T. cruzi developmental stages that dwell in the
mammalian host; ii) provide robust and reliable reagents for the improvement/development
of novel diagnostic and/or epidemiologic applications (see also [42]); and iii) were shown to
constitute appealing vaccine candidates [11] indicate that they constitute excellent targets for
molecular intervention in Chagas disease.
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